Physician profile
Anthony J Suchoski
NPI 1285838201
$89,298.38
in general payments reported to CMS, 2019-2025
20 companies · $4,625 in 2025
The $4,625 reported for 2025 was more than what 91% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $591 · 2021: $7,131 · 2022: $26K · 2023: $39K · 2024: $12K · 2025: $4,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $18K · Food and Beverage: $9,244 · Travel and Lodging: $3,596 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $975 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,606.25 |
| Consulting Fee | $17,577.00 |
| Food and Beverage | $9,243.75 |
| Travel and Lodging | $3,595.80 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $975.00 |
| Education | $212.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $33,101.11 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $23,162.60 | 2022-2025 | Sunosi |
| Harmony Biosciences LLC | $15,985.29 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $11,460.69 | 2019-2025 | |
| Zoll Respicardia, INC. | $2,044.10 | 2021-2025 | Remede System |
| Inspire Medical Systems, INC. | $863.78 | 2022-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $619.55 | 2023-2025 | Lumryz |
| Merck Sharp & Dohme LLC | $405.37 | 2020-2023 | Belsomra, Verquvo |
| Eisai INC. | $317.60 | 2020-2022 | |
| Fisher & Paykel Healthcare INC | $231.61 | 2019-2025 | Fisher & Paykel Healthcare |
| Vanda Pharmaceuticals INC. | $201.61 | 2020-2023 | Hetlioz |
| Novo Nordisk INC | $194.00 | 2025 | Wegovy |
| Lilly USA, LLC | $187.20 | 2025 | Zepbound |
| Glaxosmithkline, LLC. | $186.02 | 2024-2025 | Nucala |
| Lucid Diagnostics INC. | $115.13 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $76.42 | 2021-2024 | |
| Genzyme Corporation | $56.55 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $37.92 | 2019-2021 | |
| 3b Medical, INC. | $28.26 | 2023-2025 | Luna |
| Itamar Medical INC | $23.57 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Suchoski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.